
Blinatumomab-Related ICANS Symptoms More Prevalent Than Prior Reports
The incidence of symptoms consistent with immune effector cell-associated neurotoxicity syndrome (ICANS) following treatment with blinatumomab (Blincyto) was found to be higher than what prior reports demonstrated, according to findings from a poster …